SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Resectable NSCLCAugust 25, 2026

ALINA: fewer patients stopped adjuvant alectinib than chemotherapy; quality-of-life gains held to two years

Adjuvant alectinib was tolerated well enough for patients to stay on it for two years, and their self-reported physical and mental health improved over that period, according to the safety and health-related quality-of-life outcomes from the ALINA trial published in The Lancet Oncology. Seven of 128 patients stopped alectinib because of adverse events, compared with 15 of 120 patients who stopped platinum-based chemotherapy.
Share

In brief

  • The Lancet Oncology has published the safety and health-related quality-of-life outcomes from ALINA, the phase 3 trial that compared 24 months of adjuvant alectinib with four cycles of platinum-based chemotherapy in resected ALK-positive NSCLC. Disease-free survival, the primary endpoint, was reported previously.
  • The most common grade 3–4 adverse events were increased blood creatine phosphokinase in eight of 128 patients (6%) on alectinib, and decreased neutrophil count in 12 of 120 patients (10%) on chemotherapy.
  • Serious treatment-related adverse events occurred in two of 128 patients (2%) on alectinib and eight of 120 (7%) on chemotherapy. No deaths from adverse events were reported in either group.
  • Seven patients (5%) discontinued alectinib because of adverse events, against 15 (13%) on chemotherapy. Median safety follow-up was 24.8 months in the alectinib group and 3.7 months in the chemotherapy group.
  • Five SF-36v2 domains showed a clinically meaningful difference in improvement from baseline at week 12 with alectinib. At week 96 the mean Mental Component Summary score was 49.9 (SD 10.4) and the mean Physical Component Summary score was 48.8 (SD 7.2), against a general population norm of 50.

Study at a glance

  • Cohort: 257 patients randomly assigned between 16 August 2018 and 8 December 2021 (alectinib n=130, chemotherapy n=127); ClinicalTrials.gov NCT03456076
  • Population: resected, ALK-positive, stage IB (4 cm or larger) to IIIA NSCLC by AJCC/UICC 7th edition, ECOG performance status 0 to 1; 143 of 257 patients (56%) were Asian
  • Treatment: oral alectinib 600 mg twice daily for 24 months, or four 3-week cycles of intravenous platinum-based chemotherapy
  • Endpoints in this report: safety (secondary) and health-related quality of life (exploratory). Disease-free survival, the primary endpoint, was reported previously
  • Safety follow-up: median 24.8 months (IQR 22.0 to 24.9) on alectinib and 3.7 months (IQR 3.7 to 3.8) on chemotherapy
  • Discontinuation for adverse events: seven of 128 patients (5%) on alectinib, 15 of 120 (13%) on chemotherapy
  • Quality-of-life measure: SF-36v2 at baseline, every 3 weeks to week 12, then every 12 weeks to week 96, with norm-based scoring
  • Funding: F Hoffmann-La Roche

Creatine phosphokinase increases on alectinib, neutropenia on chemotherapy

The two treatment groups produced different grade 3–4 adverse events, and the difference follows the mechanism of each regimen. In the alectinib group the most common were increased blood creatine phosphokinase in eight of 128 patients (6%), increased alanine aminotransferase in two (2%) and increased blood bilirubin in two (2%). In the chemotherapy group they were decreased neutrophil count in 12 of 120 patients (10%), neutropenia in ten (8%) and nausea in five (4%).

The authors describe the safety of adjuvant alectinib as generally consistent with its known profile. That is the relevant question for an adjuvant indication, where the drug is given for 24 months to patients who have no detectable cancer, and where tolerability governs whether a patient completes the course.

Two serious treatment-related events on alectinib, eight on chemotherapy

Serious treatment-related adverse events occurred in two of the 128 patients treated with alectinib, one case of appendicitis and one of pneumonitis. Eight of the 120 patients treated with chemotherapy had one, most commonly gastrointestinal disorders in three patients (3%). No deaths attributed to adverse events occurred in either group.

Discontinuation is the measure that matters most for an adjuvant drug, because a patient who stops early loses the treatment effect the trial was built on. Seven patients (5%) discontinued alectinib because of adverse events. Fifteen (13%) discontinued chemotherapy. The abstract does not report how many alectinib patients required a dose reduction or interruption without stopping, which would describe the cost of staying on treatment for the two years.

A safety comparison drawn across 24.8 months and 3.7 months

The two safety datasets do not cover comparable periods. Median safety follow-up was 24.8 months in the alectinib group and 3.7 months in the chemotherapy group, because the trial gave alectinib for 24 months and chemotherapy for four 3-week cycles, and assessed safety until 28 days after the last dose in each case. Patients on alectinib were therefore observed for adverse events for close to seven times as long as patients on chemotherapy.

The difference in observation time is worth holding in view when the two columns of adverse-event rates are read side by side, since the groups were not watched for equal periods. The abstract reports the raw proportions in each group and does not report exposure-adjusted rates, which is the analysis that would put the two groups on a common footing.

Five SF-36v2 domains improved by week 12, and summary scores reached the general population norm

Health-related quality of life was measured with the SF-36v2 questionnaire at baseline, every three weeks to week 12, then every 12 weeks until recurrence, withdrawal of consent, death or week 96. Norm-based scoring was applied, and clinically meaningful changes were defined using the SF-36v2 manual rather than by a threshold the trial set for itself.

At week 12, alectinib produced a clinically meaningful difference in improvement from baseline in five domains: bodily pain, role physical, mental health, social functioning and vitality. Improvements in physical and mental quality of life were maintained across the two years of active treatment. At week 96 the mean Mental Component Summary score was 49.9 (SD 10.4) and the mean Physical Component Summary score was 48.8 (SD 7.2), close to the general population norm of 50. A patient two years into adjuvant treatment was, on these scores, reporting health much like someone drawn from the general population.

“For patients with resected ALK-positive NSCLC, adjuvant alectinib had a manageable safety profile; HRQoL improved and was maintained over 2 years of active treatment.”Dziadziuszko et al., The Lancet Oncology (2026)

An exploratory endpoint, with the quality-of-life comparison left undescribed in the abstract

The trial itself places these outcomes below its primary question. Disease-free survival was the primary endpoint and was reported previously, safety was a secondary endpoint, and health-related quality of life was exploratory. That ordering is the authors’ own, and it sets how much weight the week 12 domain findings can carry: they describe what patients reported, in a comparison the trial did not designate as confirmatory.

Several figures a reader would want are absent from the abstract. It reports no questionnaire completion rates over the 96 weeks, which govern how much the later timepoints can bear, and no numeric domain scores at week 12 for either group. It also gives no summary scores for the chemotherapy group at any timepoint, so the week 96 figures stand on their own rather than against a comparator. The trial remains ongoing.

Sources

  1. The Lancet Oncology. Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial (2026-08-24). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Maximilian Hochmair, Hidehito Horinouchi and David Planchard.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Patient Cases
Oct 04 2024
ILCS 2024
Advanced NSCLCResectable NSCLC

Patient Cases & Open Questions

} 32 min

Nuria Maria Novoa
Oct 04 2024
ILCS 2024
Resectable NSCLC

Surgical Dilemmas: Defining Resectability for Optimal Patient Outcomes in the IO Era

} 27 min

N. Novoa
Biagio Ricciuti
Oct 04 2024
ILCS 2024
Targeted Therapies

Decoding Actionable Alterations: Insights from KRAS, HER2, and c-MET

} 25 min

B. Ricciuti
Roberto Ferrara
Oct 04 2024
ILCS 2024
Targeted Therapies

Rare But Actionable: How To Target for RET, METex14 and NTRK

} 20 min

R. Ferrara
Anne-Marie Dingemans
Oct 04 2024
ILCS 2024
Targeted Therapies

Current Options in Targeting EGFR and ALK Beyond Osimertinib and Alectinib

} 25 min

A. Dingemans
Oct252026
ESMO 2026 SYMPOSIUM
SCLC

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

Learn more about the event

M. ReckS. PetersG. MountziosN. Reguart
Nov132026
ILCS 2026

The International Lung Cancer Summit 2026

Learn more about the event

S. PetersA. AddeoM. DasH. HorinouchiT. SequeiraC. LovlyD. PlanchardS. PatelA. CortelliniN. FrostG. MountziosA. Dingemans
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Sep 26 2025
ILCS 2025
SCLC

Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease

} 34 min

R. Manochakian
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
ILCS 2025
Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

A. Filippi
Sep 26 2025
ILCS 2025
Immunotherapies

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

P. Forde
Articles
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard
Oct 14 2026
RESEARCH
Resectable NSCLC

More lymph nodes examined at segmentectomy tracked with longer survival in early-stage NSCLC

J. Perentes
Oct 08 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Amivantamab, lazertinib and bevacizumab gave a 33% response rate after osimertinib in AMAZE-lung

R. StahelM. PérolA. AddeoS. Peters
Alfredo Addeo
Oct 05 2026
RESEARCH
Advanced NSCLCTargeted Therapies

A JCO review sets PACC mutations and exon 20 insertions apart from classical EGFR mutations in NSCLC

A. AddeoX. Le
Nikolaj Frost
Oct 04 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation

N. FrostM. ReckA. Cortellini
Oct 03 2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles
Oct 03 2026
RESEARCH
Advanced NSCLCTargeted Therapies

KRAS inhibitors in NSCLC: modest survival gains, inevitable resistance and combinations in early trials

V. Noronha
Oct 02 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial

X. Le
Oct 01 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Uncommon EGFR exon 19 deletions were associated with shorter PFS on osimertinib in a 111-patient study

H. Horinouchi
Oct 01 2026
RESEARCH
Targeted Therapies

RAS alterations drove resistance in about one in ten oncogene-driven lung cancers progressing on targeted therapy

B. RicciutiJ. RemonD. Planchard
Sep 30 2026
RESEARCH
Resectable NSCLC

Spread through air spaces predicted relapse after both lobectomy and segmentectomy in JCOG0802 stage IA NSCLC

S. BerezowskaL. BubendorfP. Hofman
Martin Reck
Sep 28 2026
RESEARCH
Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

M. ReckM. Hochmair
Sep 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

S. Saw
Portrait of Dr. Alexander Drilon
Sep 23 2026
CONGRESS
Advanced NSCLCTargeted Therapies

Zidesamtinib produced responses in 94% of ROS1 TKI-naive patients in ARROS-1

Sep 19 2026
RESEARCH
Resectable NSCLC

Spread through air spaces carried an HR of 2.32 for DFS in stage 1 lung adenocarcinoma

S. Saw
Sep 18 2026
INDUSTRY NEWS
Advanced NSCLCTargeted Therapies

Sevabertinib approved in the US for untreated HER2-mutant NSCLC